Las minas de mercurio de Almadén de 1939 a 1960. Estrategias de producción, modernización, y su repercusión en los obreros y la población

Almadén means in Arabic the mine, its population has always lived from and for the mine, and in the 1940s and 1950s also because of its 10,000 inhabitants, 2,500 were miners. In this article about Almaden, the largest mercury deposit in the world, three stages of its long history are contemplated: the postwar period (1939-1945), the autarky (1945-1950) and the so-called hinge decade (1950-1960), analyzing the socioeconomic context, the means of production in the underground workings and in the furnaces, the safety and health of workers, the surrounding environment, their labor relations and the international quotation of mercury in this period, allows us to know its evolution and modernization between 1939 and 1960.This article intends to contribute to the knowledge of this period so little studied in the history of Almadén, since most of the research carried out in recent years they concern the Modern Age. In addition, the Almadén case study will certainly contribute to the knowledge of industrial and mining policy in Spain in the 20th century.; Almadén significa en árabe la mina, así que su población ha vivido siempre de y para la mina, y en las décadas de 1940 y 1950 también, pues de sus 10.000 habitantes, 2.500 eran mineros. En este artículo sobre Almadén, el mayor yacimiento de mercurio del mundo, se contemplan tres etapas de su larga historia: la posguerra (1939-1945), la autarquía (1945-1950) y el llamado decenio bisagra (1950-1960), analizando el contexto socioeconómico, los medios de producción en las labores subterráneas y en los hornos, la mano de obra libre y obligada (en la posguerra), la salud y seguridad de los operarios, el medio ambiente del entorno y las relaciones laborales. Todo ello, unido a la cotización internacional del mercurio en dicho periodo, nos permite conocer la evolución y modernización del establecimiento minero de Almadén entre 1939 y 1960.Este artículo pretende contribuir así al conocimiento de esta época tan poco estudiada en la historia de Almadén, ya que la mayor parte de las investigaciones llevadas a cabo en los últimos años conciernen a la Edad Moderna. Además, el estudio del caso de Almadén contribuirá sin duda al conocimiento de la política industrial y minera en la España en el siglo XX

Revista española de pedagogía

Resumen basado en el de la publicaciónContiene anexoLa finalidad del trabajo es aportar evidencia sobre la relevancia que la evaluación del profesorado tiene en la práctica profesional de los docentes. Más específicamente, el objetivo concreto se centra en estudiar la relación entre las observaciones que los docentes dicen haber recibido por parte de diferentes agentes (feedback) y las prácticas que desarrollan en el aula. Para ello se han analizado las respuestas aportadas por los docentes de la muestra de España del estudio TALIS (Teaching and Learning International Survey) 2013. Y en primer lugar se constata que en la citada muestra, la cuarta parte de los mismos declara no haber recibido nunca ni por nadie ningún comentario o evaluación sobre la tarea, proporción que se eleva hasta casi el 30% en el caso de los centros públicos. Junto a ello parece encontrarse una cierta evidencia de que los docentes que son evaluados con mayor frecuencia y por diversidad de agentes, desarrollan en mayor grado prácticas docentes más innovadoras centradas en el aprendizaje activo de los estudiantes.ES

Viscosity and density measurements of aqueous amines at high pressures: MDEA-water and MEA-water mixtures for CO2 capture

Producción CientíficaViscosity and density are thermophysical properties crucial to characterizing any kind of fluid such as aqueous amines. These blends are becoming more and more relevant for their CO2 capture potential, such that having accurate viscosity and density measurements would prove useful. Densities and viscosities of these mixtures at atmospheric pressure may be found in the literature although it is more difficult to find values at high pressures, these potentially proving interesting when seeking to provide a full description of these fluids. Viscosity and density measurements at high pressures (up to 120 MPa) and at temperatures between 293.15 and 353.15 K of MDEA + water and MEA + water mixtures (both from 10 % to 40 % amine mass fraction) are presented in this work. Density measurements were performed with an Anton Paar DMA HPM densimeter with an expanded uncertainty (k = 2) less than ± 0.7 kg·m-3. A falling body technique was used to measure viscosities at high pressures due to its sturdiness in terms of corrosion. Details of this latter equipment are presented, including calibration using n-dodecane and uncertainty calculations, which give a relative expanded uncertainty (k = 2) of less than ± 2.4 % for the highest viscosity and ± 2.9 % for the lowest.2018-03-15Education Ministry (Spanish Government) through a FPU scholarshipProject for European Latin American Cooperation and Exchange (PEACE)Regional Government of Castilla y León through the Project VA295U1

Attenuation of mercury phytotoxicity with a high nutritional level of nitrate in alfalfa plants grown hydroponically

Mercury (Hg) is one of the most dangerous pollutant heavy metals to the environment, which causes several toxic effects in plants upon accumulation, such as induction of oxidative stress. Nitrate (NO3 – ) is the prevalent form to incorporate nitrogen (N) in higher plants, through its reduction to nitrite (NO2 – ) by the enzyme nitrate reductase (NR). We studied the physiological alterations caused by Hg (0, 6 and 30 µM) in alfalfa plants grown at two different levels of NO3 – : low, (2 mM; LN), and high (12 mM; HN) for one week using a semi-hydroponic culture system. Several parameters of oxidative stress such as lipid peroxidation, chlorophyll content, biothiol concen tration, and ascorbate peroxidase (APX) and glutathione reductase (GR) activities showed that HN plants were less affected by Hg. Nitrate reductase activity and NO3 – concentration were also altered under Hg stress, with lower impact in plants nourished with high NO3 – . Our results highlight the importance of the NO3 – nutritional status to improve tolerance to toxic metals like H

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

We report a medium-throughput drug-screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood-brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug-screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere.Acknowledgments: This work was supported by MINECO (SAF2017-89643-R, SAF2014-57243-R, SAF2015-62547-ERC) (M.V.), Fundacion FERO (IX FERO Grant for Research in Oncology) (M.V.), Fundacio La Marato de TV3 (141) (M.V.), Melanoma Research Alliance (Bristol-Myers Squibb-Melanoma Research Alliance Young Investigator Award 2017 (https://doi.org/10.48050/pc.gr.75716)) (M.V.), Beug Foundation (Prize for Metastasis Research 2017) (M.V.), Fundacion Ramon Areces (CIVP19S8163) (M.V.) and CIVP20S10662 (E.O.P.), Worldwide Cancer Research (19-0177) (M.V.), H2020-FETOPEN (828972) (M.V.), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018 (54545)) (M.V.), AECC (Coordinated Translational Groups 2017 (GCTRA16015SEOA) (M.V.), LAB AECC 2019 (LABAE19002-VALI) (M.V.), ERC CoG (864759) (M.V.), Sophien-Stiftung zur Förderung der klinischen Krebsforschung (T.W.), Promedica Stiftung (T.W.), Stiftung f€ur angewandte Krebsforschung (T.W.), Forschungskredit of the University of Zurich (FK-18-054) (T.W.), Betty and David Koetser Foundation for Brain Research (T.W.), Foundation for Applied Cancer Research in Zurich (T.W., M.W.), Comunidad de Madrid (S2017/BMD-3867 RENIM-CM and Y2018/NMT-4949 NanoLiver-CM) and European structural and investment funds (M.D.), ISCIII (PT20/00044) co-funded by FEDER “A way of making Europe” (M.D.), Ministero dell’Istruzione, dell’Universita e della Ricerca-MIUR, “Dipartimenti di Eccellenza 2018-2022”, (D15D18000410001) (L.B. and P.C.), Science Foundation Ireland Frontiers for the Future Award (19/FFP/6443) (L.Y.), Science Foundation Ireland Strategic Partnership Programme, Precision Oncology Ireland (18/SPP/3522) (L.Y.), Breast Cancer Now Fellowship Award/ with the generous support of Walk the Walk (2019AugSF1310) (D.V.), La Caixa-Severo Ochoa International PhD Program Fellowship (LCF/BQ/SO16/52270014) (L.Z.), La Caixa International PhD Program Fellowship-Marie Sklodowska-Curie (LCF/BQ/DI17/11620028) (P.G-G), MINECO-Severo Ochoa PhD Fellowship (BES-2017-081995) (L.A-E.), AECC Postdoctoral Fellowship (POSTD19016PRIE) (N.P.), Boehringer Ingelheim Fonds MD fellowship (L.M.). The contribution of the Experimental Therapeutics Programme was supported by core funding from the Spanish National Cancer Research Center (CNIO). CNIO is supported by the ISCIII, the Ministerio de Ciencia e Innovacion, and is a Severo Ochoa Center of Excellence (SEV-2015-0510). The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovacion and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). M.V. was named Ramon y Cajal Investigator (RYC-2013-13365) and is member of EMBO YIP (4053)

Regeneración de campus para la creación de un laboratorio vivo de sostenibilidad ("living lab") en el Campus de Excelencia Internacional de Moncloa

La Universidad Politécnica de Madrid (UPM) a través de su Centro de Innovación en Tecnología para el Desarrollo Humano (itdUPM) está propiciando la generación de conciencia, conocimiento y soluciones innovadoras que contribuyen al cumplimiento de los Objetivos de Desarrollo Sostenible a través de un edificio que sirve como laboratorio de prueba para nuevas tecnologías verdes y como plataforma de ideación colaborativa y activación social

I.amAble: la ciencia (química) al alcance de toda la sociedad

En este proyecto de innovación, que nace con vocación de continuar en años sucesivos, se persigue mejorar la calidad de la formación de los estudiantes de la Facultad de Ciencias Químicas (F. CC.QQ.) en el ámbito de la docencia teórico-práctica y de la divulgación científica. El trabajo ha consistido en la preparación de unos experimentos prácticos para llevarlos a cabo en centros educativos no universitarios en los que se ha tenido en cuenta la participación conjunta de personas con y sin diversidad funcional, desde una perspectiva inclusiva colaborativa. Estas actividades las han realizado los estudiantes bajo la supervisión de profesores (PDI) y personal de administración y servicios (PAS). Los experimentos se han recogido en fichas didácticas para facilitar su desarrollo y aplicación por parte de otros usuarios. En estas fichas se explica detalladamente cómo realizar las experiencias en formato de taller. Las fichas de los talleres realizados están disponibles en una página web vinculada a la Universidad Complutense bajo el título I.amAble (iamable.ucm.es). Está página ha sido construida por un estudiante de la Facultad de Informática , bajo la supervisión de profesionales, tanto de esa facultad como del Instituto de Tecnología del Conocimiento, y está abierta a contribuciones similares de otras facultades y otras instituciones. La página web está diseñada de manera que resulte lo más intuitiva y accesible posible para todo tipo de público. Entre todos los experimentos se han elegido cuatro para llevarlos a la práctica en centros educativos como actividades inclusivas en las que han participado conjuntamente personas con y sin discapacidad. Con este proyecto se pretende mejorar la calidad docente al ofrecer a los estudiantes la posibilidad de aprender enseñando mediante una actividad semipresencial. El desarrollo por parte de los estudiantes de competencias transversales en educación y en divulgación de la ciencia facilitarán algunas salidas profesionales en el ámbito educativo formal (centros de enseñanza) o informal (museos, animación sociocultural). Otro aspecto importante a resaltar es la potenciación de la colaboración entre todos los miembros de la institución universitaria. Este proyecto pretende contribuir a la mejora de la cultura científica, así como al establecimiento de puentes entre la UCM y la sociedad a la que debe servir. Finalmente, es importante subrayar que incidirá en la inclusión de las personas con discapacidad como parte de la sociedad, a través del acercamiento compartido a la ciencia (Dimensiones de inclusión social y derechos de Schalock; NAVAS MACHO, P. y otros, 2012. Derechos de las personas con discapacidad intelectual: implicaciones de la Convención de Naciones Unidas. Siglo Cero. 43 (243): 7-28.)

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

We report a medium‐throughput drug‐screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood–brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug‐screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understanding of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models of brain metastasis resistant to WBRT, we identified activation of the S100A9-RAGE-NF-κB-JunB pathway in brain metastases as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary melanoma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively, we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer that balances therapeutic benefit and toxicity.info:eu-repo/semantics/publishedVersio

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio